Forte Biosciences (FBRX) Retained Earnings (2016 - 2026)
Forte Biosciences (FBRX) reported Retained Earnings of -$245.5 million for Q1 2026, down 44.67% year-over-year from -$443.7 million in Q1 2025, and down 8183433.33% quarter-over-quarter from $3000.0 in Q4 2025.
Forte Biosciences (FBRX) Retained Earnings (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 11 years of Retained Earnings data on file, last reported at -$245.5 million in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$245.5 million, down 44.67% year-over-year; the trailing twelve-month figure through Mar 2026 was -$245.5 million (down 44.67% YoY), and the FY2025 annual result was $3000.0, up 100.0% from the prior year.
- Retained Earnings eased to -$245.5 million in Q1 2026 per FBRX's latest filing, from $3000.0 in the prior quarter.
- Over five years, Retained Earnings peaked at $4000.0 in Q4 2023 and troughed at -$245.5 million in Q1 2026.
- A 5-year average of -$105.5 million and a median of -$102.7 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings jumped 100.0% in 2023, then plunged 3850050.0% in 2024.
- A 5-year view of Retained Earnings shows it stood at -$87.0 million in 2022, then surged by 100.0% to $4000.0 in 2023, then sank by 3850050.0% to -$154.0 million in 2024, then surged by 100.0% to $3000.0 in 2025, then slumped by 8183433.33% to -$245.5 million in 2026.
- Business Quant data shows FBRX's Retained Earnings at -$245.5 million in Q1 2026, $3000.0 in Q4 2025, and -$6000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - | -245.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -245.50 Mn |
| Dec 31, 2025 | 3,000.00 |
| Sep 30, 2025 | -6,000.00 |
| Jun 30, 2025 | -180.90 Mn |
| Mar 31, 2025 | -169.70 Mn |
| Dec 31, 2024 | -154.00 Mn |
| Sep 30, 2024 | -146.80 Mn |
| Jun 30, 2024 | -138.50 Mn |
| Mar 31, 2024 | -125.94 Mn |
| Dec 31, 2023 | 4,000.00 |
| Sep 30, 2023 | -112.60 Mn |
| Jun 30, 2023 | -102.69 Mn |
| Mar 31, 2023 | -93.80 Mn |
| Dec 31, 2022 | -87.04 Mn |
| Sep 30, 2022 | -82.20 Mn |
| Jun 30, 2022 | -78.80 Mn |
| Mar 31, 2022 | -75.70 Mn |
| Dec 31, 2021 | -73.17 Mn |
| Sep 30, 2021 | -69.82 Mn |
| Jun 30, 2021 | -62.07 Mn |